CAMBRIDGE, Mass., Nov. 6,
2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc.
(NASDAQ: INFI) today announced that it will host a reception for
investors and analysts on Friday, November
10, 2017, from 6:00 a.m. to 8:00
a.m. to discuss the clinical development of IPI-549,
including a review of data from the ongoing Phase 1/1b clinical
study. The reception will take place in conjunction with the 2017
Society for Immunotherapy of Cancer (SITC) Annual Meeting at the
Gaylord National Hotel and Convention Center in National Harbor,
MD. IPI-549 is an orally administered immuno-oncology development
candidate that selectively inhibits phosphoinositide-3-kinase gamma
(PI3K-gamma) and is believed to be the only PI3K-gamma inhibitor in
clinical development.
Featured speakers at the reception will include:
- David Hong, M.D., Deputy Chair,
Department of Investigational Cancer Therapeutics, Division of
Cancer Medicine, The University of
Texas MD Anderson Cancer Center, Houston, TX
- Taha Merghoub, Ph.D., Co-Director, Ludwig Collaborative
Laboratory and the Swim Across America Laboratory at Memorial Sloan
Kettering
The presentation portion of the reception will be webcast
beginning at 6:30 a.m. ET. The
webcast and accompanying slides can be accessed in the
"investors/media" section of the company's website, www.infi.com. A
replay of the event will also be available.
About the IPI-549 and the Ongoing Phase 1 Study
IPI-549 is an investigational, orally administered immuno-oncology
development candidate that selectively inhibits PI3K-gamma. In
preclinical studies, IPI-549 reprograms macrophages from a
pro-tumor, M2, to an anti-tumor, M1, phenotype and is able to
overcome resistance to checkpoint inhibition as well as to enhance
the activity of checkpoint inhibitors.1,2 As such,
IPI-549 may have the potential to treat a broad range of solid
tumors and represents a potentially complementary approach to
restoring anti-tumor immunity in combination with other
immunotherapies such as checkpoint inhibitors.
A Phase 1 study of IPI-549 in patients with advanced solid
tumors is ongoing to evaluate the safety, tolerability, activity,
pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy
and in combination with Opdivo in approximately 200 patients with
advanced solid tumors.3 The four-part study includes
monotherapy and combination dose-escalation components, in addition
to monotherapy expansion and combination expansion components.
Patient enrollment is complete in monotherapy dose-escalation, and
monotherapy expansion is ongoing. Combination dose-escalation is
also ongoing, and combination expansion is expected to begin in the
second half of 2017.
The combination expansion component includes multiple cohorts
designed to evaluate IPI-549 in patients with specific types of
cancer, including patients with non-small cell lung cancer (NSCLC),
melanoma, and head and neck squamous cell carcinoma (HNSCC) whose
tumors show initial resistance or subsequently develop resistance
to immune checkpoint blockade therapy. This combination expansion
will also include a cohort of patients with triple negative breast
cancer (TNBC) who have not been previously exposed to immune
checkpoint blockade therapy. Although there has been great progress
in the treatment of cancer, there remains a need for additional
treatment options. NSCLC, melanoma, HNSCC and TNBC account for more
than 22 percent of all new cancer cases in the
U.S.4,5
IPI-549 is an investigational compound and its safety and
efficacy has not been evaluated by the U.S. Food and Drug
Administration or any other health authority.
About Infinity
Infinity is an innovative
biopharmaceutical company dedicated to advancing novel medicines
for people with cancer. Infinity is developing IPI-549, an oral
immuno-oncology development candidate that selectively inhibits
PI3K-gamma. A Phase 1 study in patients with advanced solid tumors
is ongoing. For more information on Infinity, please refer to
Infinity's website at www.infi.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995
including those regarding the company's expectations about the
timing and type of data presentations, the therapeutic potential of
PI3K-gamma inhibition and of IPI-549, alone or in combination with
other agents, and clinical trial plans regarding IPI-549. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from the company's current expectations, including, for
example, that there is no guarantee that IPI-549 will successfully
complete necessary preclinical and clinical development phases, or
gain regulatory approval, and other risks described in greater
detail under the caption "Risk Factors" included in Infinity's
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) on August 3, 2017, and other filings
filed by Infinity with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Infinity expressly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
OPDIVO® is a registered trademark of Bristol-Myers
Squibb.
Contact:
Jaren Irene
Madden, Senior Director, Investor Relations and Corporate
Communications
617-453-1336 or Jaren.Madden@infi.com
1 Kaneda, M., Messer, K., Ralainirina, N., Li, H., et
al. PI3Kγ is a molecular switch that controls immune suppression.
Nature, 2016 Nov;539:437-442.
2 De Henau, O., Rausch, M., Winkler, D., Campesato, L., et al. Overcoming
resistance to checkpoint blockade therapy by targeting PI3Kγ in
myeloid cells. Nature, 2016 Nov;539:443-447.
3 www.clinicaltrials.gov, NCT02637531.
4 American Cancer Society, Cancer Facts and Statistics
2017,
http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016/index
and
http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-key-statistics,
Last Accessed September 19, 2017.
5 Conquer Cancer Foundation, Head and Neck Cancer
Statistics,
http://www.cancer.net/cancer-types/head-and-neck-cancer/statistics,
Last Accessed September 19, 2017.
View original
content:http://www.prnewswire.com/news-releases/infinity-to-host-investor-reception-and-webcast-at-sitc-300549448.html
SOURCE Infinity Pharmaceuticals, Inc.